Source comparison
MOTS-c vs SLU-PP-332: Research Application Comparison
Primary Mechanism AMPK activation → metabolic reprogramming ERβ agonism → mitochondrial gene transcription MOTS-c targets upstream energy sensing; SLU-PP-332 acts on downstream transcription Route of Administration Subcutaneous injection Oral administration SL
This comparison does not assign a generated winner or score.
- Primary Mechanism
- AMPK activation → metabolic reprogramming
- ERβ agonism → mitochondrial gene transcription
- MOTS-c targets upstream energy sensing; SLU-PP-332 acts on downstream transcription
- Route of Administration
- Subcutaneous injection
- Oral administration
- SLU-PP-332 offers convenience but requires daily dosing due to shorter half-life
- Insulin Sensitivity Effect
- Direct enhancement via GLUT4 translocation
- Indirect. Improved via increased oxidative capacity
- MOTS-c shows stronger glucose homeostasis impact in metabolic dysfunction models
- Muscle Endurance Impact
- 20–30% increase in preclinical models
- 70% increase in published rodent trials
- SLU-PP-332 outperforms in endurance-specific metrics but lacks metabolic breadth
- Hormonal Disruption Risk
- Negligible. No receptor-mediated activity
- Low. ERα-sparing design avoids feminizing effects
- Both have favorable safety profiles, but SLU-PP-332 requires monitoring for off-target ERα binding
- Current Clinical Evidence
- Phase I safety trials underway; limited human data
- Preclinical only. No published human trials as of 2026
- MOTS-c has progressed further toward clinical translation